Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia

An Italian retrospective study

Emilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, Massimo Gentile, Antonella Montanini, Accursio Augello, Velia Bongarzoni, Alfonso D'Arco, Nicola Di Renzo, Rita Fazzi, Giovanni Franco, Roberto Marasca, Antonino Mulè, Maurizio Musso, Pellegrino Musto, Elsa Pennese, Andrea Piccin, Delia Rota-Scalabrini, Giuseppe Visani, Luigi Rigacci

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies=3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100mg/m2 per day, range 90-130mg/m2 per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P=0·014) and in those responsive to the previous treatment (P=0·04). After a median follow-up of 7·9months (range 1-148), the median progression-free survival was 16months and the median duration of response was 13months. Median overall survival (OS) was 16·8months for the whole cohort; patients not responding to the treatment had a significantly worse outcome than those who attained a response (P=0·0001). In multivariate analysis, only resistant disease status at start of bendamustine treatment (HR 3·2, 95% CI 1·4-7·3, P=0·006) had an independent prognostic value for OS. Toxicity was manageable and mostly haematological. In conclusion, in our experience R-B was an effective and well-tolerated treatment for relapsed/refractory CLL patients, producing a remarkable high CR rate and mild toxicity.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalBritish Journal of Haematology
Volume153
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Retrospective Studies
Therapeutics
Survival
Bendamustine Hydrochloride
Rituximab
Disease-Free Survival
Multivariate Analysis

Keywords

  • Antineoplastic agents
  • Bendamustine
  • Leukaemia
  • Relapsed chronic lymphocytic leukaemia
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia : An Italian retrospective study. / Iannitto, Emilio; Morabito, Fortunato; Mancuso, Salvatrice; Gentile, Massimo; Montanini, Antonella; Augello, Accursio; Bongarzoni, Velia; D'Arco, Alfonso; Di Renzo, Nicola; Fazzi, Rita; Franco, Giovanni; Marasca, Roberto; Mulè, Antonino; Musso, Maurizio; Musto, Pellegrino; Pennese, Elsa; Piccin, Andrea; Rota-Scalabrini, Delia; Visani, Giuseppe; Rigacci, Luigi.

In: British Journal of Haematology, Vol. 153, No. 3, 05.2011, p. 351-357.

Research output: Contribution to journalArticle

Iannitto, E, Morabito, F, Mancuso, S, Gentile, M, Montanini, A, Augello, A, Bongarzoni, V, D'Arco, A, Di Renzo, N, Fazzi, R, Franco, G, Marasca, R, Mulè, A, Musso, M, Musto, P, Pennese, E, Piccin, A, Rota-Scalabrini, D, Visani, G & Rigacci, L 2011, 'Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: An Italian retrospective study', British Journal of Haematology, vol. 153, no. 3, pp. 351-357. https://doi.org/10.1111/j.1365-2141.2011.08597.x
Iannitto, Emilio ; Morabito, Fortunato ; Mancuso, Salvatrice ; Gentile, Massimo ; Montanini, Antonella ; Augello, Accursio ; Bongarzoni, Velia ; D'Arco, Alfonso ; Di Renzo, Nicola ; Fazzi, Rita ; Franco, Giovanni ; Marasca, Roberto ; Mulè, Antonino ; Musso, Maurizio ; Musto, Pellegrino ; Pennese, Elsa ; Piccin, Andrea ; Rota-Scalabrini, Delia ; Visani, Giuseppe ; Rigacci, Luigi. / Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia : An Italian retrospective study. In: British Journal of Haematology. 2011 ; Vol. 153, No. 3. pp. 351-357.
@article{7ac496a8eb66473099d68700cddb0a04,
title = "Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: An Italian retrospective study",
abstract = "To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66years (range 39-85). Forty-three percent of patients had relapsed and 57{\%} were resistant (median previous therapies=3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100mg/m2 per day, range 90-130mg/m2 per day). The overall response rate was 69·6{\%} (complete response 28·6{\%}; partial response 41{\%}), and was significantly higher in patients treated with R-B (P=0·014) and in those responsive to the previous treatment (P=0·04). After a median follow-up of 7·9months (range 1-148), the median progression-free survival was 16months and the median duration of response was 13months. Median overall survival (OS) was 16·8months for the whole cohort; patients not responding to the treatment had a significantly worse outcome than those who attained a response (P=0·0001). In multivariate analysis, only resistant disease status at start of bendamustine treatment (HR 3·2, 95{\%} CI 1·4-7·3, P=0·006) had an independent prognostic value for OS. Toxicity was manageable and mostly haematological. In conclusion, in our experience R-B was an effective and well-tolerated treatment for relapsed/refractory CLL patients, producing a remarkable high CR rate and mild toxicity.",
keywords = "Antineoplastic agents, Bendamustine, Leukaemia, Relapsed chronic lymphocytic leukaemia, Rituximab",
author = "Emilio Iannitto and Fortunato Morabito and Salvatrice Mancuso and Massimo Gentile and Antonella Montanini and Accursio Augello and Velia Bongarzoni and Alfonso D'Arco and {Di Renzo}, Nicola and Rita Fazzi and Giovanni Franco and Roberto Marasca and Antonino Mul{\`e} and Maurizio Musso and Pellegrino Musto and Elsa Pennese and Andrea Piccin and Delia Rota-Scalabrini and Giuseppe Visani and Luigi Rigacci",
year = "2011",
month = "5",
doi = "10.1111/j.1365-2141.2011.08597.x",
language = "English",
volume = "153",
pages = "351--357",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia

T2 - An Italian retrospective study

AU - Iannitto, Emilio

AU - Morabito, Fortunato

AU - Mancuso, Salvatrice

AU - Gentile, Massimo

AU - Montanini, Antonella

AU - Augello, Accursio

AU - Bongarzoni, Velia

AU - D'Arco, Alfonso

AU - Di Renzo, Nicola

AU - Fazzi, Rita

AU - Franco, Giovanni

AU - Marasca, Roberto

AU - Mulè, Antonino

AU - Musso, Maurizio

AU - Musto, Pellegrino

AU - Pennese, Elsa

AU - Piccin, Andrea

AU - Rota-Scalabrini, Delia

AU - Visani, Giuseppe

AU - Rigacci, Luigi

PY - 2011/5

Y1 - 2011/5

N2 - To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies=3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100mg/m2 per day, range 90-130mg/m2 per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P=0·014) and in those responsive to the previous treatment (P=0·04). After a median follow-up of 7·9months (range 1-148), the median progression-free survival was 16months and the median duration of response was 13months. Median overall survival (OS) was 16·8months for the whole cohort; patients not responding to the treatment had a significantly worse outcome than those who attained a response (P=0·0001). In multivariate analysis, only resistant disease status at start of bendamustine treatment (HR 3·2, 95% CI 1·4-7·3, P=0·006) had an independent prognostic value for OS. Toxicity was manageable and mostly haematological. In conclusion, in our experience R-B was an effective and well-tolerated treatment for relapsed/refractory CLL patients, producing a remarkable high CR rate and mild toxicity.

AB - To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies=3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100mg/m2 per day, range 90-130mg/m2 per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P=0·014) and in those responsive to the previous treatment (P=0·04). After a median follow-up of 7·9months (range 1-148), the median progression-free survival was 16months and the median duration of response was 13months. Median overall survival (OS) was 16·8months for the whole cohort; patients not responding to the treatment had a significantly worse outcome than those who attained a response (P=0·0001). In multivariate analysis, only resistant disease status at start of bendamustine treatment (HR 3·2, 95% CI 1·4-7·3, P=0·006) had an independent prognostic value for OS. Toxicity was manageable and mostly haematological. In conclusion, in our experience R-B was an effective and well-tolerated treatment for relapsed/refractory CLL patients, producing a remarkable high CR rate and mild toxicity.

KW - Antineoplastic agents

KW - Bendamustine

KW - Leukaemia

KW - Relapsed chronic lymphocytic leukaemia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79954424213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954424213&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08597.x

DO - 10.1111/j.1365-2141.2011.08597.x

M3 - Article

VL - 153

SP - 351

EP - 357

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -